Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization

SAN DIEGO, Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Orexigen Therapeutics (OREX) announced today that it has successfully completed its previously announced acquisition of the United States rights to Contrave® (naltrexone HCl/bupropio... Biopharmaceuticals, Acquisitions, Product Launch Orexigen Therapeutics, Contrave, naltrexone, bupropion
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news